[go: up one dir, main page]

MX2017014300A - Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. - Google Patents

Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Info

Publication number
MX2017014300A
MX2017014300A MX2017014300A MX2017014300A MX2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A MX 2017014300 A MX2017014300 A MX 2017014300A
Authority
MX
Mexico
Prior art keywords
inhibitors
compositions
methods
same
deacetilase
Prior art date
Application number
MX2017014300A
Other languages
English (en)
Other versions
MX378983B (es
Inventor
Dominguez Celia
A Luckhurst Christopher
J Stott Andrew
C Maillard Michel
F Haughan Alan
Van De Poël Amanda
A Saville-Stones Elizabeth
Wishart Grant
Wall Michael
Breccia Perla
E Jarvis Rebecca
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017014300A publication Critical patent/MX2017014300A/es
Publication of MX378983B publication Critical patent/MX378983B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Se proporcionan ciertos inhibidores de la histona deacetilasa (HDAC) de Fórmula (I), sus composiciones y los métodos de su uso. (ver Fórmula).
MX2017014300A 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. MX378983B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017014300A true MX2017014300A (es) 2018-08-09
MX378983B MX378983B (es) 2025-03-10

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014300A MX378983B (es) 2015-05-07 2016-05-06 Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.

Country Status (11)

Country Link
US (2) US10053434B2 (es)
EP (1) EP3291810B1 (es)
JP (1) JP6805172B2 (es)
KR (1) KR20180002729A (es)
CN (1) CN107735088B (es)
AU (1) AU2016258188B2 (es)
CA (1) CA2984618C (es)
EA (1) EA036965B1 (es)
IL (1) IL255448B2 (es)
MX (1) MX378983B (es)
WO (1) WO2016179554A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX379817B (es) 2015-05-07 2025-03-11 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
CA2984618C (en) * 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10757941B2 (en) * 2016-07-22 2020-09-01 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
CA3149096A1 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
US20240327361A1 (en) * 2021-02-15 2024-10-03 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005313108B2 (en) 2004-12-10 2011-05-26 Msd Italia S.R.L. Heterocycle derivatives as histone deacetylase (HDAC) inhibitors
MX341133B (es) 2010-01-13 2016-08-08 Tempero Pharmaceuticals Inc * Compuestos y metodos para la inhibición de hdac.
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
JP6047563B2 (ja) * 2011-07-08 2016-12-21 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
EP3243515B1 (en) * 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
MX2014006409A (es) * 2011-11-28 2014-07-30 Novartis Ag Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
BR112014024693A2 (pt) 2012-04-05 2017-07-11 Chdi Foundation Inc composto de fórmula / ou um sal farmaceuticamente aceitável ou pró-fármaco do mesmo; composto; composição farmacêutica; método de tratamento de uma afecção ou distúrbio mediado por atividade de quinurenina 3-mono-oxigenase em um indivíduo que necessita de tal tratamento
MX379817B (es) 2015-05-07 2025-03-11 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
CA2984618C (en) * 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
CA2987570C (en) 2015-07-27 2021-06-15 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos

Also Published As

Publication number Publication date
CN107735088B (zh) 2021-11-02
CA2984618C (en) 2024-01-09
EP3291810B1 (en) 2022-08-10
AU2016258188B2 (en) 2021-08-26
AU2016258188A1 (en) 2017-11-23
EA201792247A1 (ru) 2018-06-29
EP3291810A1 (en) 2018-03-14
MX378983B (es) 2025-03-10
HK1252487A1 (en) 2019-05-24
JP6805172B2 (ja) 2020-12-23
IL255448A0 (en) 2017-12-31
IL255448B2 (en) 2023-07-01
EP3291810A4 (en) 2018-11-07
WO2016179554A1 (en) 2016-11-10
CN107735088A (zh) 2018-02-23
CA2984618A1 (en) 2016-11-10
IL255448B1 (en) 2023-03-01
US20190202795A1 (en) 2019-07-04
BR112017023711A2 (pt) 2018-07-17
JP2018515489A (ja) 2018-06-14
EA036965B1 (ru) 2021-01-20
US20160326124A1 (en) 2016-11-10
KR20180002729A (ko) 2018-01-08
US10053434B2 (en) 2018-08-21

Similar Documents

Publication Publication Date Title
MX379817B (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
MX2017014300A (es) Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
EA201891211A1 (ru) Ингибиторы cxcr2
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2019012434A (es) Agentes inductores de apoptosis.
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
EP3624804A4 (en) HISTONE DEACETYLASE INHIBITORS (HDAC)
HK1220407A1 (zh) 组蛋白去乙酰酶抑制剂，其组合物及其使用方法
CO2020007895A2 (es) Inhibidores de histona acetiltransferasa de la familia myst
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA201590028A1 (ru) Ингибиторы гистондеацетилазы и их композиции и способы их применения
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina